Zevalin ibritumomab tiuxetan regulatory update

IDPH said European approval for Zevalin radioimmunotherapy has been delayed because of compliance issues at the fill/finish provider,

Read the full 184 word article

How to gain access

Continue reading with a
two-week free trial.